The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
AGC kinases, mechanisms of regulation and innovative drug development
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Other kinases demonstrate that nucleotide binding can either enhance or reduce the affinity for substrates (37–39) and can also contribute to dimerization (40, 41).”
From Local and distal changes in dynamics are caused by an L205R Cushing’s syndrome mutant in PRKACA (2025) · cites this paper as [39]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases
Cargnello, M., & Roux, P. P. (2011) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00031-10 · Cited by 3,274
Mechanisms of Hippo pathway regulation
Meng, Z., Moroishi, T., & Guan, K.-L. (2016) · Genes & Development · doi:10.1101/gad.274027.115 · Cited by 1,667
An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor
Zhang, X., Gureasko, J., Shen, K., Cole, P. A., & Kuriyan, J. (2006) · Cell · doi:10.1016/j.cell.2006.05.013 · Cited by 1,650
The nuts and bolts of AGC protein kinases
Pearce, L. R., Komander, D., & Alessi, D. R. (2010) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2822 · Cited by 1,294
Regulation and function of ribosomal protein S6 kinase (S6K) within mTOR signalling networks
Magnuson, B., Ekim, B., & Fingar, D. C. (2012) · Biochemical Journal · doi:10.1042/bj20110892 · Cited by 1,015
(Patho)physiological Significance of the Serum- and Glucocorticoid-Inducible Kinase Isoforms
Lang, F., Böhmer, C., Palmada, M., Seebohm, G., Strutz-Seebohm, N., & Vallon, V. (2006) · Physiological Reviews · doi:10.1152/physrev.00050.2005 · Cited by 689
Alessi, D. R., Barry Caudwell, F., Andjelkovic, M., Hemmings, B. A., & Cohen, P. (1996) · FEBS Letters · doi:10.1016/s0014-5793(96)01370-1 · Cited by 628
Catalytic Control in the EGF Receptor and Its Connection to General Kinase Regulatory Mechanisms
Jura, N., Zhang, X., Endres, N. F., Seeliger, M. A., Schindler, T., & Kuriyan, J. (2011) · Molecular Cell · doi:10.1016/j.molcel.2011.03.004 · Cited by 310
Frödin, M., Antal, T. L., Dümmler, B. A., Jensen, C. J., Deak, M., Gammeltoft, S., & Biondi, R. M. (2002) · The EMBO Journal · doi:10.1093/emboj/cdf551 · Cited by 275
Self-citationPDK1 Regulates Cancer Cell Motility by Antagonising Inhibition of ROCK1 by RhoE
Pinner, S., & Sahai, E. (2008) · Nature Cell Biology · doi:10.1038/ncb1675 · Cited by 267
Fang, Z., Grütter, C., & Rauh, D. (2013) · ACS Chemical Biology · doi:10.1021/cb300663j · Cited by 197
Ultanir, S. K., Hertz, N. T., Li, G., Ge, W.-P., Burlingame, A. L., Pleasure, S. J., Shokat, K. M., Jan, L. Y., & Jan, Y.-N. (2012) · Neuron · doi:10.1016/j.neuron.2012.01.019 · Cited by 131
Alfonso, S. I., Callender, J. A., Hooli, B., Antal, C. E., Mullin, K., Sherman, M. A., Lesné, S. E., Leitges, M., Newton, A. C., Tanzi, R. E., et al. (2016) · Science Signaling · doi:10.1126/scisignal.aaf6209 · Cited by 103
Kim, J., Masterson, L. R., Cembran, A., Verardi, R., Shi, L., Gao, J., Taylor, S. S., & Veglia, G. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1502299112 · Cited by 45
Research works printed but not linked: 164
- Pawson, 2005, Protein phosphorylation in signaling–50 years and counting, Trends Biochem. Sci., 30, 286, 10.1016/j.tibs.2005.04.013 · DOI · Paper page
- Manning, 2002, The protein kinase complement of the human genome, Science, 298, 1912, 10.1126/science.1075762 · DOI · Paper page
- Arencibia, 2013, AGC protein kinases: from structural mechanism of regulation to allosteric drug development for the treatment of human diseases, Biochim. Biophys. Acta, 1834, 1302, 10.1016/j.bbapap.2013.03.010 · DOI · Paper page
- Zhang, 2009, AGCVIII kinases: at the crossroads of cellular signaling, Trends Plant Sci., 14, 689, 10.1016/j.tplants.2009.09.006 · DOI
- Cohen, 2002, Protein kinases–the major drug targets of the twenty-first century?, Nat. Rev. Drug Discov., 1, 309, 10.1038/nrd773 · DOI · Paper page
- Hergovich, 2013, Regulation and functions of mammalian LATS/NDR kinases: looking beyond canonical Hippo signalling, Cell Biosci., 3, 32, 10.1186/2045-3701-3-32 · DOI
- Rath, 2012, Rho-associated kinases in tumorigenesis: re-considering ROCK inhibition for cancer therapy, EMBO Rep., 13, 900, 10.1038/embor.2012.127 · DOI · Paper page
- Turnham, 2016, Protein kinase A catalytic subunit isoform PRKACA; History, function and physiology, Gene, 577, 101, 10.1016/j.gene.2015.11.052 · DOI · Paper page
- Pretre, 2017, Inhibition of Akt and other AGC kinases: a target for clinical cancer therapy?, Semin. Cancer Biol.
- Lindsley, 2014, Philip S. Portoghese Medicinal Chemistry Lectureship: drug discovery targeting allosteric sites, J. Med. Chem., 57, 7485, 10.1021/jm5011786 · DOI
- Knighton, 1991, Crystal structure of the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase, Science, 253, 407, 10.1126/science.1862342 · DOI · Paper page
- Taylor, 2013, PKA: lessons learned after twenty years, Biochim. Biophys. Acta., 1834, 1271, 10.1016/j.bbapap.2013.03.007 · DOI · Paper page
- Zheng, 1993, Crystal structure of the catalytic subunit of cAMP-dependent protein kinase complexed with MgATP and peptide inhibitor, Biochemistry, 32, 2154, 10.1021/bi00060a005 · DOI · Paper page
- Huse, 2002, The conformational plasticity of protein kinases, Cell, 109, 275, 10.1016/S0092-8674(02)00741-9 · DOI · Paper page
- Kornev, 2015, Dynamics-driven allostery in protein kinases, Trends Biochem. Sci., 40, 628, 10.1016/j.tibs.2015.09.002 · DOI · Paper page
- Hindie, 2009, Structure and allosteric effects of low molecular weight activators on the protein kinase PDK1, Nat. Chem. Biol., 5, 758, 10.1038/nchembio.208 · DOI
- Leslie, 2001, Phosphoinositide-regulated kinases and phosphoinositide phosphatases, Chem. Rev., 101, 2365, 10.1021/cr000091i · DOI
- Newton, 2003, Regulation of the ABC kinases by phosphorylation: protein kinase C as a paradigm, Biochem. J., 370, 361, 10.1042/bj20021626 · DOI · Paper page
- Yang, 2002, Crystal structure of an activated Akt/protein kinase B ternary complex with GSK3-peptide and AMP-PNP, Nat. Struct. Biol., 9, 940, 10.1038/nsb870 · DOI · Paper page
- Kemp, 1975, Substrate specificity of the cyclic AMP-dependent protein kinase, Proc. Natl. Acad. Sci. U. S. A., 72, 3448, 10.1073/pnas.72.9.3448 · DOI · Paper page
- Pinna, 1996, How do protein kinases recognize their substrates?, Biochim. Biophys. Acta, 1314, 191, 10.1016/S0167-4889(96)00083-3 · DOI · Paper page
- Biondi, 2000, Identification of a pocket in the PDK1 kinase domain that interacts with PIF and the C-terminal residues of PKA, EMBO J., 19, 979, 10.1093/emboj/19.5.979 · DOI · Paper page
- Biondi, 2002, High resolution crystal structure of the human PDK1 catalytic domain defines the regulatory phosphopeptide docking site, EMBO J., 21, 4219, 10.1093/emboj/cdf437 · DOI · Paper page
- Hauge, 2007, Mechanism for activation of the growth factor-activated AGC kinases by turn motif phosphorylation, EMBO J., 26, 2251, 10.1038/sj.emboj.7601682 · DOI
- Nolen, 2004, Regulation of protein kinases; controlling activity through activation segment conformation, Mol. Cell, 15, 661, 10.1016/j.molcel.2004.08.024 · DOI · Paper page
- Dettori, 2009, Regulation of the interaction between protein kinase C-related protein kinase 2 (PRK2) and its upstream kinase: 3-phosphoinositide-dependent protein kinase 1 (PDK1), J. Biol. Chem., 284, 30318, 10.1074/jbc.M109.051151 · DOI
- Yang, 2002, Molecular mechanism for the regulation of protein kinase B/Akt by hydrophobic motif phosphorylation, Mol. Cell, 9, 1227, 10.1016/S1097-2765(02)00550-6 · DOI · Paper page
- Zhang, 2014, Molecular mechanism of regulation of the atypical protein kinase C by N-terminal domains and an allosteric small compound, Chem. Biol., 21, 754, 10.1016/j.chembiol.2014.04.007 · DOI
- Hindie, 2012, Use of a fluorescent ATP analog to probe the allosteric conformational change in the active site of the protein kinase PDK1, Methods Mol. Biol., 928, 133, 10.1007/978-1-62703-008-3_10 · doi:10.1007/978-1-62703-008-3_10
- Busschots, 2012, Substrate-selective inhibition of protein kinase PDK1 by small compounds that bind to the PIF-Pocket allosteric docking site, Chem. Biol., 19, 1152, 10.1016/j.chembiol.2012.07.017 · DOI
- Lopez-Garcia, 2011, Allosteric regulation of protein kinase PKCzeta by the N-terminal C1 domain and small compounds to the PIF-pocket, Chem. Biol., 18, 1463, 10.1016/j.chembiol.2011.08.010 · DOI
- Bauer, 2012, Regulation of protein kinase C-related protein kinase 2 (PRK2) by an intermolecular PRK2-PRK2 interaction mediated by its N-terminal domain, J. Biol. Chem., 287, 20590, 10.1074/jbc.M111.327437 · DOI
- Baumli, 2008, The structure of P-TEFb (CDK9/cyclin T1): its complex with flavopiridol and regulation by phosphorylation, EMBO J., 27, 1907, 10.1038/emboj.2008.121 · DOI · Paper page
- Frodin, 2000, A phosphoserine-regulated docking site in the protein kinase RSK2 that recruits and activates PDK1, EMBO J., 19, 2924, 10.1093/emboj/19.12.2924 · DOI · Paper page
- Biondi, 2001, The PIF-binding pocket in PDK1 is essential for activation of S6K and SGK: but not PKB, EMBO J., 20, 4380, 10.1093/emboj/20.16.4380 · DOI · Paper page
- Stegert, 2004, Regulation of NDR2 protein kinase by multi-site phosphorylation and the S100B calcium-binding protein, J. Biol. Chem., 279, 23806, 10.1074/jbc.M402472200 · DOI
- Cook, 2014, Constitutively active NDR1-PIF kinase functions independent of MST1 and hMOB1 signalling, Cell. Signal., 26, 1657, 10.1016/j.cellsig.2014.04.011 · DOI
- Hoa, 2016, The characterisation of LATS2 kinase regulation in Hippo-YAP signalling, Cell. Signal., 28, 488, 10.1016/j.cellsig.2016.02.012 · DOI
- Sadowsky, 2011, Turning a protein kinase on or off from a single allosteric site via disulfide trapping, Proc. Natl. Acad. Sci. U S A, 108, 6056, 10.1073/pnas.1102376108 · DOI
- Frohner, 2011, 4-Benzimidazolyl-3-phenylbutanoic acids as novel pif-pocket-targeting allosteric inhibitors of protein kinase PKCzeta, J. Med. Chem., 54, 6714, 10.1021/jm2005892 · DOI
- Stroba, 2009, 3,5-Diphenylpent-2-enoic acids as allosteric activators of the protein kinase PDK1: structure-activity relationships and thermodynamic characterization of binding as paradigms for PIF-binding pocket-targeting compounds, J. Med. Chem., 52, 4683, 10.1021/jm9001499 · DOI
- Engel, 2006, Allosteric activation of the protein kinase PDK1 with low molecular weight compounds, EMBO J., 25, 5469, 10.1038/sj.emboj.7601416 · DOI
- Wilhelm, 2012, 2-(3-Oxo-1,3-diphenylpropyl)malonic acids as potent allosteric ligands of the PIF pocket of phosphoinositide-dependent kinase-1: development and prodrug concept, J. Med. Chem., 55, 9817, 10.1021/jm3010477 · DOI
- Schulze, 2016, Bidirectional allosteric communication between the ATP-binding site and the regulatory PIF pocket in PDK1 protein kinase, Cell Chem. Biol., 23, 1193, 10.1016/j.chembiol.2016.06.017 · DOI · Paper page
- Kroon, 2015, Discovery of a potent allosteric kinase modulator by combining computational and synthetic methods, Angew. Chem. Int. Ed., 54, 13933, 10.1002/anie.201506310 · DOI
- Rettenmaier, 2014, A small-molecule mimic of a peptide docking motif inhibits the protein kinase PDK1, Proc. Natl. Acad. Sci. U. S. A., 111, 18590, 10.1073/pnas.1415365112 · DOI
- Stockman, 2009, Identification of allosteric PIF-pocket ligands for PDK1 using NMR-based fragment screening and 1H-15N TROSY experiments, Chem. Biol. Drug Des., 73, 179, 10.1111/j.1747-0285.2008.00768.x · DOI
- Wei, 2010, Design and synthesis of benzoazepin-2-one analogs as allosteric binders targeting the PIF pocket of PDK1, Bioorg. Med. Chem. Lett., 20, 3897, 10.1016/j.bmcl.2010.05.019 · DOI
- Gagliardi, 2015, PDK1: a signaling hub for cell migration and tumor invasion, Biochim. Biophys. Acta, 1856, 178
- Armando, 2017, PDK1: at the crossroad of cancer signaling pathways, Semin. Cancer Biol.
- Vanhaesebroeck, 2000, The PI3K-PDK1 connection: more than just a road to PKB, Biochem. J., 346, 561, 10.1042/bj3460561 · doi:10.1042/bj3460561 · Paper page
- Zurashvili, 2013, Interaction of PDK1 with phosphoinositides is essential for neuronal differentiation but dispensable for neuronal survival, Mol. Cell. Biol., 33, 1027, 10.1128/MCB.01052-12 · DOI
- Bayascas, 2008, Dissecting the role of the 3-phosphoinositide-dependent protein kinase-1 (PDK1) signalling pathways, Cell Cycle, 7, 2978, 10.4161/cc.7.19.6810 · DOI
- McManus, 2004, The in vivo role of PtdIns(3,4,5)P3 binding to PDK1 PH domain defined by knockin mutation, EMBO J., 23, 2071, 10.1038/sj.emboj.7600218 · DOI
- Lucas, 2011, Phosphatidylserine binding is essential for plasma membrane recruitment and signaling function of 3-phosphoinositide-dependent kinase-1, J. Biol. Chem., 286, 41265, 10.1074/jbc.M111.300806 · DOI
- Vonkova, 2015, Lipid cooperativity as a general membrane-recruitment principle for PH domains, Cell Rep., 12, 1519, 10.1016/j.celrep.2015.07.054 · DOI
- King, 2000, Sphingosine is a novel activator of 3-phosphoinositide-dependent kinase 1, J. Biol. Chem., 275, 18108, 10.1074/jbc.M909663199 · DOI
- Pastor-Flores, 2016, Lipid regulators of Pkh2 in Candida albicans, the protein kinase ortholog of mammalian PDK1, Biochim. Biophys. Acta-Mol. Cell Biology Lipids, 1861, 249, 10.1016/j.bbalip.2015.12.016 · DOI
- Pastor-Flores, 2013, PIF-pocket as a target for C. albicans Pkh selective inhibitors, ACS Chem. Biol., 8, 2283, 10.1021/cb400452z · DOI
- Masters, 2010, Regulation of 3-phosphoinositide-dependent protein kinase 1 activity by homodimerization in live cells, Sci. Signal., 3, ra78, 10.1126/scisignal.2000738 · DOI
- Kang, 2013, Transition from heterotypic to homotypic PDK1 homodimerization is essential for TCR-mediated NF-kappaB activation, J. Immunol., 190, 4508, 10.4049/jimmunol.1202923 · DOI
- Calleja, 2014, Acute regulation of PDK1 by a complex interplay of molecular switches, Biochem. Soc. Trans., 42, 1435, 10.1042/BST20140222 · DOI
- Balendran, 2000, A 3-phosphoinositide-dependent protein kinase-1 (PDK1) docking site is required for the phosphorylation of protein kinase Czeta (PKCzeta) and PKC-related kinase 2 by PDK1, J. Biol. Chem., 275, 20806, 10.1074/jbc.M000421200 · DOI · Paper page
- Collins, 2003, In vivo role of the PIF-binding docking site of PDK1 defined by knock-in mutation, EMBO J., 22, 4202, 10.1093/emboj/cdg407 · DOI · Paper page
- Gao, 2001, The carboxyl terminus of protein kinase c provides a switch to regulate its interaction with the phosphoinositide-dependent kinase: PDK-1, J. Biol. Chem., 276, 19588, 10.1074/jbc.M101357200 · DOI
- Toker, 2000, Cellular signaling: pivoting around PDK-1, Cell, 103, 185, 10.1016/S0092-8674(00)00110-0 · DOI · Paper page
- Dutil, 1998, Regulation of conventional protein kinase C isozymes by phosphoinositide-dependent kinase 1 (PDK-1), Curr. Biol., 8, 1366, 10.1016/S0960-9822(98)00017-7 · DOI · Paper page
- Bayascas, 2006, Evaluation of approaches to generation of tissue-specific knock-in mice, J. Biol. Chem., 281, 28772, 10.1074/jbc.M606789200 · DOI
- Collins, 2005, In vivo role of the phosphate groove of PDK1 defined by knockin mutation, J. Cell Sci., 118, 5023, 10.1242/jcs.02617 · DOI
- Balzano, 2015, Alternative activation mechanisms of protein kinase B trigger distinct downstream signaling responses, J. Biol. Chem., 290, 24975, 10.1074/jbc.M115.651570 · DOI
- Najafov, 2011, Characterization of GSK2334470: a novel and highly specific inhibitor of PDK1, Biochem. J., 433, 357, 10.1042/BJ20101732 · DOI
- Toker, 2014, Signaling specificity in the Akt pathway in biology and disease, Adv. Biol. Regul., 55, 28, 10.1016/j.jbior.2014.04.001 · DOI · Paper page
- Hers, 2011, Akt signalling in health and disease, Cell. Signal., 23, 1515, 10.1016/j.cellsig.2011.05.004 · DOI · Paper page
- Bozulic, 2009, PIKKing on PKB: regulation of PKB activity by phosphorylation, Curr. Opin. Cell Biol., 21, 256, 10.1016/j.ceb.2009.02.002 · DOI · Paper page
- Wu, 2010, Crystal structure of human AKT1 with an allosteric inhibitor reveals a new mode of kinase inhibition, PLoS One, 5, e12913, 10.1371/journal.pone.0012913 · DOI · Paper page
- Ebner, 2017, PI(3,4,5)P3 engagement restricts akt activity to cellular membranes, Mol. Cell, 65, 416, 10.1016/j.molcel.2016.12.028 · DOI · Paper page
- Mattmann, 2011, Inhibition of Akt with small molecules and biologics: historical perspective and current status of the patent landscape, Expert. Opin. Ther. Pat., 21, 1309, 10.1517/13543776.2011.587959 · DOI
- Nitulescu, 2016, Akt inhibitors in cancer treatment: the long journey from drug discovery to clinical use (Review), Int. J. Oncol., 48, 869, 10.3892/ijo.2015.3306 · DOI · Paper page
- Lindsley, 2005, Allosteric Akt (PKB) inhibitors: discovery and SAR of isozyme selective inhibitors, Bioorg. Med. Chem. Lett., 15, 761, 10.1016/j.bmcl.2004.11.011 · DOI · Paper page
- Lapierre, 2016, Discovery of 3-(3-(4-(1-aminocyclobutyl)phenyl)-5-phenyl-3H-imidazo[4,5-b]pyridin-2-yl)pyridin -2-amine (ARQ 092): an orally bioavailable, selective, and potent allosteric AKT inhibitor, J. Med. Chem., 59, 6455, 10.1021/acs.jmedchem.6b00619 · DOI
- Dudley, 1995, A synthetic inhibitor of the mitogen-activated protein kinase cascade, Proc. Natl. Acad. Sci. U. S. A., 92, 7686, 10.1073/pnas.92.17.7686 · DOI · Paper page
- Alessi, 1995, PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo, J. Biol. Chem., 270, 27489, 10.1074/jbc.270.46.27489 · DOI · Paper page
- Lu, 2015, The mechanism of ATP-dependent allosteric protection of akt kinase phosphorylation, Structure, 23, 1725, 10.1016/j.str.2015.06.027 · DOI · Paper page
- Rosse, 2010, PKC and the control of localized signal dynamics, Nat. Rev. Mol. Cell Biol., 11, 103, 10.1038/nrm2847 · DOI · Paper page
- Kazanietz, 2005, Targeting protein kinase C and non-kinase phorbol ester receptors: emerging concepts and therapeutic implications, Biochim. Biophys. Acta, 1754, 296, 10.1016/j.bbapap.2005.07.034 · DOI
- Antal, 2015, Cancer-associated protein kinase C mutations reveal kinase's role as tumor suppressor, Cell, 160, 489, 10.1016/j.cell.2015.01.001 · DOI · Paper page
- AC, 2017, Protein kinase C as a tumor suppressor, Semin. Cancer Biol.
- Garg, 2014, Protein kinase C and cancer: what we know and what we do not, Oncogene, 33, 5225, 10.1038/onc.2013.524 · DOI · Paper page
- Kazanietz, 2011, Protein kinase C regulation: C1 meets C-tail, Structure, 19, 144, 10.1016/j.str.2011.01.004 · DOI
- Newton, 2010, Protein kinase C: poised to signal, Am. J. Physiol. Endocrinol. Metab., 298, E395, 10.1152/ajpendo.00477.2009 · DOI · Paper page
- Parker, 2001, AGC protein kinase phosphorylation and protein kinase C, Biochem. Soc. Trans., 29, 860, 10.1042/bst0290860 · DOI
- Parker, 2014, Atypical protein kinase Ciota as a human oncogene and therapeutic target, Biochem. Pharmacol., 88, 1, 10.1016/j.bcp.2013.10.023 · DOI
- Murray, 2011, Protein kinase Ciota expression and oncogenic signaling mechanisms in cancer, J. Cell. Physiol., 226, 879, 10.1002/jcp.22463 · DOI
- Farese, 2012, Atypical protein kinase C in cardiometabolic abnormalities, Curr. Opin. Lipidol., 23, 175, 10.1097/MOL.0b013e328352c4c7 · DOI
- Sommese, 2017, The Role of Regulatory Domains in Maintaining Autoinhibition in the Multidomain Kinase PKCalpha, J. Biol. Chem., 292, 2873, 10.1074/jbc.M116.768457 · DOI
- Kirwan, 2003, Inhibition of protein kinase C catalytic activity by additional regions within the human protein kinase Calpha-regulatory domain lying outside of the pseudosubstrate sequence, Biochem. J., 373, 571, 10.1042/bj20030011 · doi:10.1042/bj20030011
- Leonard, 2011, Crystal structure and allosteric activation of protein kinase C betaII, Cell, 144, 55, 10.1016/j.cell.2010.12.013 · DOI · Paper page
- Lucic, 2016, Novel features of DAG-activated PKC isozymes reveal a conserved 3-D architecture, J. Mol. Biol., 428, 121, 10.1016/j.jmb.2015.11.001 · DOI
- Antal, 2015, Intramolecular C2 domain-mediated autoinhibition of protein kinase C betaII, Cell Rep., 12, 1252, 10.1016/j.celrep.2015.07.039 · DOI
- Arencibia, 2017, An Allosteric Inhibitor Scaffold Targeting the PIF-Pocket of Atypical Protein Kinase C Isoforms, ACS Chem. Biol., 12, 564, 10.1021/acschembio.6b00827 · DOI
- O'Sullivan, 2017, Regulation of protein kinase C-related kinase (PRK) signalling by the TPalpha and TPbeta isoforms of the human thromboxane A2 receptor: Implications for thromboxane- and androgen- dependent neoplastic and epigenetic responses in prostate cancer, Biochim Biophys Acta, 1863, 838, 10.1016/j.bbadis.2017.01.011 · DOI
- Davies, 2000, Specificity and mechanism of action of some commonly used protein kinase inhibitors, Biochem. J., 351, 95, 10.1042/bj3510095 · DOI · Paper page
- Lachmann, 2011, Regulatory domain selectivity in the cell-type specific PKN-dependence of cell migration, PLoS One, 6, e21732, 10.1371/journal.pone.0021732 · DOI
- Shiga, 2009, Development of an intracellularly acting inhibitory peptide selective for PKN, Biochem. J., 425, 445, 10.1042/BJ20090380 · DOI
- Mukai, 2003, The structure and function of PKN: a protein kinase having a catalytic domain homologous to that of PKC, J. Biochem., 133, 17, 10.1093/jb/mvg019 · DOI · Paper page
- Flynn, 2000, Rho GTPase control of protein kinase C-related protein kinase activation by 3-phosphoinositide-dependent protein kinase, J. Biol. Chem., 275, 11064, 10.1074/jbc.275.15.11064 · DOI
- Keshwani, 2011, Hydrophobic motif phosphorylation is not required for activation loop phosphorylation of p70 ribosomal protein S6 kinase 1 (S6K1), J. Biol. Chem., 286, 23552, 10.1074/jbc.M111.258004 · DOI
- Romeo, 2012, Regulation and function of the RSK family of protein kinases, Biochem. J., 441, 553, 10.1042/BJ20110289 · DOI · Paper page
- Houles, 2017, Defining the role of the RSK isoforms in cancer, Semin. Cancer Biol.
- Hauge, 2006, RSK and MSK in MAP kinase signalling, J. Cell Sci., 119, 3021, 10.1242/jcs.02950 · DOI · Paper page
- Weng, 1995, Multiple independent inputs are required for activation of the p70 S6 kinase, Mol. Cell. Biol., 15, 2333, 10.1128/MCB.15.5.2333 · DOI · Paper page
- Bruhn, 2010, Second AKT: the rise of SGK in cancer signalling, Growth Factors, 28, 394, 10.3109/08977194.2010.518616 · DOI · Paper page
- Sommer, 2013, Elevated SGK1 predicts resistance of breast cancer cells to Akt inhibitors, Biochem. J., 452, 499, 10.1042/BJ20130342 · DOI
- Chun, 2002, The Na(+)/H(+) exchanger regulatory factor 2 mediates phosphorylation of serum- and glucocorticoid-induced protein kinase 1 by 3-phosphoinositide-dependent protein kinase 1, Biochem. Biophys. Res. Commun., 298, 207, 10.1016/S0006-291X(02)02428-2 · DOI
- Bayliss, 2003, Structural basis of Aurora-A activation by TPX2 at the mitotic spindle, Mol. Cell, 12, 851, 10.1016/S1097-2765(03)00392-7 · DOI · Paper page
- Elkins, 2012, Crystal structure of human Aurora B in complex with INCENP and VX-680, J. Med. Chem., 55, 7841, 10.1021/jm3008954 · doi:10.1021/jm3008954
- Otto, 2009, Stabilization of N-Myc is a critical function of Aurora A in human neuroblastoma, Cancer Cell, 15, 67, 10.1016/j.ccr.2008.12.005 · DOI · Paper page
- Gustafson, 2014, Drugging MYCN through an allosteric transition in Aurora kinase A, Cancer Cell, 26, 414, 10.1016/j.ccr.2014.07.015 · DOI · Paper page
- Dauch, 2016, A MYC-aurora kinase A protein complex represents an actionable drug target in p53-altered liver cancer, Nat. Med., 22, 744, 10.1038/nm.4107 · DOI · Paper page
- Brockmann, 2013, Small molecule inhibitors of aurora-a induce proteasomal degradation of N-myc in childhood neuroblastoma, Cancer Cell, 24, 75, 10.1016/j.ccr.2013.05.005 · DOI · Paper page
- Richards, 2016, Structural basis of N-Myc binding by Aurora-A and its destabilization by kinase inhibitors, Proc. Natl. Acad. Sci. U. S. A., 113, 13726, 10.1073/pnas.1610626113 · DOI · Paper page
- Zheng, 2016, Nuclear AURKA acquires kinase-independent transactivating function to enhance breast cancer stem cell phenotype, Nat. Commun., 7, 10180, 10.1038/ncomms10180 · DOI · Paper page
- Burgess, 2016, Allosteric inhibition of Aurora-A kinase by a synthetic vNAR domain, Open Biol., 6, 10.1098/rsob.160089 · DOI
- Strebhardt, 2010, Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy, Nat. Rev. Drug Discov., 9, 643, 10.1038/nrd3184 · DOI · Paper page
- Raab, 2014, Quantitative chemical proteomics reveals a Plk1 inhibitor-compromised cell death pathway in human cells, Cell Res., 24, 1141, 10.1038/cr.2014.86 · DOI
- Cheng, 2003, The crystal structure of the human polo-like kinase-1 polo box domain and its phospho-peptide complex, EMBO J., 22, 5757, 10.1093/emboj/cdg558 · DOI · Paper page
- Elia, 2003, The molecular basis for phosphodependent substrate targeting and regulation of Plks by the Polo-box domain, Cell, 115, 83, 10.1016/S0092-8674(03)00725-6 · DOI · Paper page
- Xu, 2013, Structural basis for the inhibition of Polo-like kinase 1, Nat. Struct. Mol. Biol., 20, 1047, 10.1038/nsmb.2623 · DOI
- Zhu, 2016, Phospho-pon binding-mediated fine-tuning of Plk1 activity, Structure, 24, 1110, 10.1016/j.str.2016.04.012 · DOI
- Ni, 2015, Structural basis for Mob1-dependent activation of the core Mst-Lats kinase cascade in Hippo signaling, Genes Dev., 29, 1416, 10.1101/gad.264929.115 · DOI · Paper page
- Xiong, 2017, Regulation of Protein Interactions by Mps One Binder (MOB1) Phosphorylation, Mol. Cell Proteomics., 16, 1111, 10.1074/mcp.M117.068130 · DOI
- Kim, 2016, Structural basis for autoinhibition and its relief of MOB1 in the Hippo pathway, Sci. Rep., 6, 28488, 10.1038/srep28488 · DOI
- Rock, 2013, Activation of the yeast Hippo pathway by phosphorylation-dependent assembly of signaling complexes, Science, 340, 871, 10.1126/science.1235822 · DOI
- Gogl, 2015, The structure of an NDR/LATS kinase-mob complex reveals a novel kinase-coactivator system and substrate docking mechanism, PLoS Biol., 13, e1002146, 10.1371/journal.pbio.1002146 · DOI
- Street, 2011, Rho kinase proteins–pleiotropic modulators of cell survival and apoptosis, Anticancer Res., 31, 3645
- Jacobs, 2006, The structure of dimeric ROCK I reveals the mechanism for ligand selectivity, J. Biol. Chem., 281, 260, 10.1074/jbc.M508847200 · DOI · Paper page
- Heikkila, 2011, Co-crystal structures of inhibitors with MRCKbeta, a key regulator of tumor cell invasion, PLoS One, 6, e24825, 10.1371/journal.pone.0024825 · DOI
- Elkins, 2009, Structure of dystrophia myotonica protein kinase, Protein Sci., 18, 782, 10.1002/pro.82 · DOI
- Truebestein, 2015, A molecular ruler regulates cytoskeletal remodelling by the Rho kinases, Nat. Commun., 6, 10029, 10.1038/ncomms10029 · DOI
- Truebestein, 2016, Made to measure − keeping Rho kinase at a distance, Small GTPases, 7, 82, 10.1080/21541248.2016.1173770 · DOI
- Zhang, 2003, Homodimerization through coiled-coil regions enhances activity of the myotonic dystrophy protein kinase, FEBS Lett., 546, 281, 10.1016/S0014-5793(03)00601-X · DOI
- Gagliardi, 2014, PDK1-mediated activation of MRCKalpha regulates directional cell migration and lamellipodia retraction, J. Cell Biol., 206, 415, 10.1083/jcb.201312090 · DOI
- Pitcher, 1998, G protein-coupled receptor kinases, Annu. Rev. Biochem., 67, 653, 10.1146/annurev.biochem.67.1.653 · DOI · Paper page
- Nogués, 2017, G protein-coupled receptor kinases (GRKs) in tumorigenesis and cancer progression: GPCR regulators and signaling hubs, Semin. Cancer Biol.
- Lodowski, 2003, Keeping G proteins at bay: a complex between G protein-coupled receptor kinase 2 and Gbetagamma, Science, 300, 1256, 10.1126/science.1082348 · DOI · Paper page
- Boguth, 2010, Molecular basis for activation of G protein-coupled receptor kinases, EMBO J., 29, 3249, 10.1038/emboj.2010.206 · DOI
- Huang, 2011, Recognition in the face of diversity: interactions of heterotrimeric G proteins and G protein-coupled receptor (GPCR) kinases with activated GPCRs, J. Biol. Chem., 286, 7715, 10.1074/jbc.R109.051847 · DOI
- Huang, 2009, A surface of the kinase domain critical for the allosteric activation of G protein-coupled receptor kinases, J. Biol. Chem., 284, 17206, 10.1074/jbc.M809544200 · DOI
- Pao, 2009, Role of the amino terminus of G protein-coupled receptor kinase 2 in receptor phosphorylation, Biochemistry, 48, 7325, 10.1021/bi900408g · DOI
- Beautrait, 2014, Mapping the putative G protein-coupled receptor (GPCR) docking site on GPCR kinase 2: insights from intact cell phosphorylation and recruitment assays, J. Biol. Chem., 289, 25262, 10.1074/jbc.M114.593178 · DOI
- Sapio, 2014, Targeting protein kinase A in cancer therapy: an update, EXCLI J., 13, 843
- Francis, 2010, cGMP-dependent protein kinases and cGMP phosphodiesterases in nitric oxide and cGMP action, Pharmacol. Rev., 62, 525, 10.1124/pr.110.002907 · DOI · Paper page
- Browning, 2010, cGMP-dependent protein kinases as potential targets for colon cancer prevention and treatment, Fut. Med. Chem., 2, 65, 10.4155/fmc.09.142 · DOI
- Windham, 2015, cGMP signaling as a target for the prevention and treatment of breast cancer, Semin. Cancer Biol., 31, 106, 10.1016/j.semcancer.2014.06.006 · DOI
- Taylor, 2012, Assembly of allosteric macromolecular switches: lessons from PKA, Nat. Rev. Mol. Cell Biol., 13, 646, 10.1038/nrm3432 · DOI · Paper page
- Sjoberg, 2010, Dissecting the cAMP-inducible allosteric switch in protein kinase A RIalpha, Protein Sci., 19, 1213, 10.1002/pro.400 · DOI
- Francis, 2002, Mechanisms of autoinhibition in cyclic nucleotide-dependent protein kinases, Front. Biosci., 7, d580, 10.2741/A796 · doi:10.2741/a796
- Burgoyne, 2007, Cysteine redox sensor in PKGIa enables oxidant-induced activation, Science, 317, 1393, 10.1126/science.1144318 · DOI · Paper page
- Prysyazhna, 2012, Single atom substitution in mouse protein kinase G eliminates oxidant sensing to cause hypertension, Nat. Med., 18, 286, 10.1038/nm.2603 · DOI · Paper page
- Rudyk, 2012, Nitroglycerin fails to lower blood pressure in redox-dead Cys42Ser PKG1alpha knock-in mouse, Circulation, 126, 287, 10.1161/CIRCULATIONAHA.112.101287 · DOI
- Moon, 2013, The switch helix: a putative combinatorial relay for interprotomer communication in cGMP-dependent protein kinase, Biochim. Biophys. Acta, 1834, 1346, 10.1016/j.bbapap.2013.02.009 · doi:10.1016/j.bbapap.2013.02.009
- Antal, 2014, Intramolecular conformational changes optimize protein kinase C signaling, Chem. Biol., 21, 459, 10.1016/j.chembiol.2014.02.008 · DOI
- Sudol, 2010, Modularity in the Hippo signaling pathway, Trends Biochem. Sci., 35, 627, 10.1016/j.tibs.2010.05.010 · DOI · Paper page
- Zitouni, 2014, Polo-like kinases: structural variations lead to multiple functions, Nat. Rev. Mol. Cell Biol., 15, 433, 10.1038/nrm3819 · DOI · Paper page
Cited by
Crosstalk between circRNAs and the PI3K/AKT signaling pathway in cancer progression
Xue, C., Li, G., Lu, J., & Li, L. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00788-w · Cited by 268
Wu, X., Yang, Z., Zou, J., Gao, H., Shao, Z., Li, C., & Lei, P. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02179-x · Cited by 88
Molecular profiling of sponge deflation reveals an ancient relaxant-inflammatory response
Ruperti, F., Becher, I., Stokkermans, A., Wang, L., Marschlich, N., Potel, C., Maus, E., Stein, F., Drotleff, B., Schippers, K. J., et al. (2024) · Current Biology · doi:10.1016/j.cub.2023.12.021 · Cited by 23
Of rings and spines: The multiple facets of Citron proteins in neural development
Bianchi, F. T., Gai, M., Berto, G. E., & Di Cunto, F. (2020) · Small GTPases · doi:10.1080/21541248.2017.1374325 · Cited by 19
“protein displays a modular organization very similar to other members of the Myotonic Dystrophy subfamily of AGC-kinases, such as Rho-kinases (ROCKs) and CDC42BPA/ CDC42BPB (also known as MRCKs), which are the closest CIT-K relatives.(4,5) CIT-K shares with MRCKs an amino-terminal kinase domain, followed by an extende…”
BackgroundThe comprehensive SARS-CoV-2 ‘hijackome’ knowledge base
Huuskonen, S., Liu, X., Pöhner, I., Redchuk, T., Salokas, K., Lundberg, R., Maljanen, S., Belik, M., Reinholm, A., Kolehmainen, P., et al. (2024) · Cell Discovery · doi:10.1038/s41421-024-00748-y · Cited by 12
Metadata
- Authors
- Leroux, A. E., Schulze, J. O., & Biondi, R. M.
- Venue
- Seminars in Cancer Biology
- Publisher
- Elsevier BV
- Published
- 2018-02
- Volume
- 48
- Pages
- 1-17
- ISSN
- 1044-579X
- Cited by
- 159
- References
- 14
- Language
- en
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Funders
- Europrofession Foundation
- University of Saarland, the University of Frankfurt
- DFG
- D-Krebshilfe
- BMBF
- CONICET
- ANPCyT
- FOCEM-Mercosur (COF 03/11)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.